Na Hyun Kim
Overview
Explore the profile of Na Hyun Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
424
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Sun C, Chen Y, Kim N, Lowe S, Ma S, Zhou Z, et al.
Front Genet
. 2022 Aug;
13:911740.
PMID: 35910202
Gastric cancer (GC) is a common cancer with high mortality. This study aimed to identify its differentially expressed genes (DEGs) using bioinformatics methods. DEGs were screened from four GEO (Gene...
22.
Kim N, Han J, Bae W, Kim J, Lee K, Lee H, et al.
Korean J Fam Med
. 2022 Jul;
43(4):225-230.
PMID: 35903045
Background: Since the era of "thyroid cancer epidemic," many Korean academic societies discouraged the use of ultrasonography in healthy individuals and revised the Korean Thyroid Imaging Reporting and Data System...
23.
Kim O, Choi B, Kim D, Kim N, Rho J, Sul W, et al.
Am J Cancer Res
. 2022 Jun;
12(5):2350-2362.
PMID: 35693079
Lung cancer is the primary cause of cancer-related deaths worldwide. Recently, although the microbiome has emerged as the key modulator of the carcinogenesis, it has not been evaluated in lung...
24.
Kang Y, Koo B, Kim O, Park J, Kim H, Lee H, et al.
Microbiol Spectr
. 2022 May;
10(3):e0020722.
PMID: 35587206
A rapid and sensitive diagnosis is crucial for the management of tuberculosis (TB). A simple and label-free approach via homobifunctional imidoesters with a microfluidic platform (SLIM) assay showed a higher...
25.
Park Y, Kim M, Choi Y, Kim N, Kim L, Hong S, et al.
J Immunother Cancer
. 2022 Mar;
10(3).
PMID: 35347071
Immunotherapy has fundamentally changed the landscape of cancer treatment. However, only a subset of patients respond to immunotherapy, and a significant portion experience immune-related adverse events (irAEs). In addition, the...
26.
Sun C, Ma S, Chen Y, Kim N, Kailas S, Wang Y, et al.
Front Oncol
. 2022 Mar;
12:843880.
PMID: 35311155
Background: Liver cancer (LC) is well known for its prevalence as well as its poor prognosis. The aberrant expression of lysyl oxidase () family is associated with liver cancer, but...
27.
Ding P, Guo H, Sun C, Yang P, Kim N, Tian Y, et al.
BMC Gastroenterol
. 2022 Mar;
22(1):121.
PMID: 35287591
Background: Previous studies have confirmed that systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) can predict the prognosis and chemotherapy efficacy of various malignant tumors. However, to the best...
28.
Choi H, Kim N, Lee J, Choi D, Seo Y, Cho W, et al.
Ophthalmic Epidemiol
. 2021 Feb;
28(6):488-494.
PMID: 33522358
: We aimed to investigate the prevalence and risk factors of dry eye syndrome (DES) among a population-based cohort study.: This cross-sectional study was conducted on 475 subjects (184 men...
29.
Shah T, Reddy D, Peters M, Ball D, Kim N, Gomez Gomez E, et al.
Prostate Cancer Prostatic Dis
. 2021 Jan;
24(2):567-574.
PMID: 33504940
Introduction: Focal therapy (FT) ablates areas of prostate cancer rather than treating the whole gland. We compared oncological outcomes of FT to radical prostatectomy (RP). Methods: Using prospective multicentre databases...
30.
Sun C, Ahmed M, Kim N, Thapa P, Memon B, Manem N, et al.
Infect Control Hosp Epidemiol
. 2021 Jan;
43(2):272-273.
PMID: 33397538
No abstract available.